Zentalis Pharma Appoints New CMO, Dr. Melissa Johnson
Ticker: ZNTL · Form: 8-K · Filed: May 29, 2024 · CIK: 1725160
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
Zentalis Pharma has a new CMO, Dr. Melissa Johnson, replacing Dr. Lori Friedman.
AI Summary
Zentalis Pharmaceuticals, Inc. announced on May 24, 2024, the appointment of Dr. Melissa L. Johnson as Chief Medical Officer, effective immediately. Dr. Johnson previously served as Executive Vice President and Chief Medical Officer at Verastem Oncology. The company also announced the departure of Dr. Lori J. Friedman from her role as Chief Medical Officer.
Why It Matters
The appointment of a new Chief Medical Officer can signal a shift in the company's strategic direction for clinical development and research.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can indicate strategic shifts or internal challenges that may impact future drug development and regulatory approvals.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Registrant
- Dr. Melissa L. Johnson (person) — Appointed Chief Medical Officer
- Dr. Lori J. Friedman (person) — Departing Chief Medical Officer
- Verastem Oncology (company) — Previous employer of Dr. Johnson
FAQ
Who has been appointed as the new Chief Medical Officer at Zentalis Pharmaceuticals?
Dr. Melissa L. Johnson has been appointed as the new Chief Medical Officer.
When was the appointment of Dr. Melissa L. Johnson effective?
The appointment was effective immediately as of May 24, 2024.
What was Dr. Melissa L. Johnson's previous role?
Dr. Johnson previously served as Executive Vice President and Chief Medical Officer at Verastem Oncology.
Who has departed from the role of Chief Medical Officer at Zentalis Pharmaceuticals?
Dr. Lori J. Friedman has departed from the role of Chief Medical Officer.
What is the effective date of the reported changes?
The earliest event reported is dated May 24, 2024.
Filing Stats: 797 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-05-29 07:04:29
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ZNTL The Nasdaq Glo
- $45,000 — hich provides for an annual retainer of $45,000 for his Board service, and additional a
- $10,000 — vice, and additional annual retainer of $10,000 for his service as a member of the Audi
- $850,000, b — f shares was determined by dividing (i) $850,000, by (ii) the average closing price per sha
- $425,000, b — stock as is determined by dividing (i) $425,000, by (ii) the average closing price per sha
Filing Documents
- zntl-20240524.htm (8-K) — 32KB
- 0001725160-24-000120.txt ( ) — 156KB
- zntl-20240524.xsd (EX-101.SCH) — 2KB
- zntl-20240524_lab.xml (EX-101.LAB) — 22KB
- zntl-20240524_pre.xml (EX-101.PRE) — 13KB
- zntl-20240524_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: May 29, 2024 By: /s/ Kimberly Blackwell, M.D. Kimberly Blackwell, M.D. Chief Executive Officer